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Evaluation of: Iida N, Dzutsev A, Stewart CA et al.: Commensal bacteria control cancer 
response to therapy by modulating the tumor microenvironment. Science 342, 967-970 
(2013). Intestinal microbiota is essential for host physiological process including the 
maintenance of epithelial barrier and the immune functions. However, paradoxically, 
the intestinal microbiota can promote various types of experimental carcinogenesis. The 
current paper demonstrates that disruption of the microbiota impairs the response of 
tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy in a 
context-dependent manner. Thus, intestinal microbiota may have great impacts on the 
tumor response to chemotherapy and/or immunotherapy. 
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Microbial community is present abundantly in mucosal organs including the intestine, the 
oral cavity, and the vagina, and is referred as the microbiota [1]. Microbiota and host form 
complex and intricate relationships, which confer the benefits to the host in many ways. 
However, this close relationship can incite diseases, when homeostasis between host and 
microbiota is disturbed [1]. Human intestinal microbiota consists of tens of trillions of 
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microorganisms, occupying 99 % of the microbial mass in the whole body, and can exert 
both local and long-distance effects on various types of pathological conditions. Germ-free 
(GF) mice without intestinal microbiota are resistant to various types of experimental 
carcinogenesis in intestine, stomach, and liver [2-4]. Thus, the intestinal microbiota can 
promote carcinogenesis, probably by activating pathogen-associated molecular pattern 
recognition receptors such as Toll-like receptors (TLRs) [4] and NOD-like receptors (NLRs) 
[5], generating bacteria-derived genotoxins [6] and virulence factors [7], and modulating the 
metabolism in host [8]. 
 
Summary of methods & results 
In the current paper [9], Iida et al. revealed that intestinal commensal bacteria could control 
the responsiveness of tumors to immunotherapy using CpG-oligodeoxynucleotides (ODN) or 
platinum chemotherapy. Combined treatment with CpG-ODN, a ligand for TLR9, and 
anti-IL-10 receptor (R) antibody, retards tumor growth and prolongs survival in MC38- or 
B16-tumor bearing mice by inducing intra-tumoral myeloid cell-derived TNF-α-mediated 
hemorrhagic necrosis. An antibiotic cocktail (ABX) of vancomycin, imipenem, and 
neomycin reduces anti-IL-10R/CpG-ODN-mediated tumor necrosis and subsequent tumor 
retardation in wild-type (WT) but not Rag1-/- mice. ABX significantly reduced TNF 
expression, TNF-expressing cell numbers, and the expression of other pro-inflammatory 
cytokines but not anti-inflammatory cytokine expression in MC38 tumor sites. Likewise, 
when tumor-bearing GF and specific pathogen-free (SPF) mice were treated with 
anti-IL-10R/CpG-ODN, tumors of GF mice produced significantly lower amount of TNF and 
IL-12, compared with SPF mice. Gavage administration of LPS restored TNF expression in 
tumors of ABX-treated WT but not Tlr4-/- mice. Moreover, Tlr4 but not Tlr2 deficiency 
resulted in lower induction of TNF expression and reduced tumor regression after 
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immunotherapy. Thus, intestinal microbiota primes tumor-associated myeloid cells for 
anti-IL-10R/CpG-ODA-induced inflammatory cytokine production, mainly by using TLR4 
pathway. 
The examination on fecal microbiota composition under several conditions revealed that 
Alispteps and Lactobacillus genii correlated positively and negatively with TNF production, 
respectively. The administration of cultured Alispteps shaii by gavage to mice pre-exposed to 
ABX reconstituted the ability of tumor-associated myeloid cells to produce TNF while that of 
Lactobacillus fermentum to intact mice attenuated the response to anti-IL-10R/CpG-ODN. 
Thus, these species can influence the tumor response to CpG-ODN by affecting 
tumor-associated myeloid cells. 
The authors examined also the effects of intestinal microbiota on the response to therapy 
using platinum agents such as oxaliplatin and cisplatin. Oxaliplatin eradicated most 
subcutaneous EL4 tumors and prolonged survival, but ABX-treated animals exhibited 
significantly reduced tumor regression and survival. Likewise, GF animals failed to respond 
to oxaliplatin treatment. Similar observations were also obtained on the effects of ABX on 
the response of MC38-bearing mice to oxaliplatin and that of EL4-bearing mice to cisplatin. 
Both oxaliplatin and cisplatin induce the formation of platinum DNA adducts and intra-strand 
cross-links, and eventually generate reactive oxygen species (ROS) to cause DNA damage 
and apoptosis [10]. Despite of few effects on the levels of DNA-bound platinum, ABX 
treatment reduced platinum-induced ROS generation together with reduction in gene 
expression of Nox1 and Cybb encoding ROS-generating NADPH oxidase 2 (NOX2) and that 
of ROS-responsive Nos2, Sod1, and Sod2. Moreover, oxaliplatin increased ROS production 
in tumor-infiltrating neutrophils and macrophages, while this response was impaired in 
ABX-treated or Cybb-/- mice. Furthermore, depletion of myeloid cells impaired the ability of 
oxaliplatin to induce tumor regression and to increase survival. Myd88 deficiency impaired 
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the early antitumor effect of oxaliplatin, while Tlr4 deficiency had a partial effect on 
long-term tumor growth and survival. Thus, tumor-infiltrating myeloid cells produce most of 
the ROS required for oxaliplatin genotoxicity, by sensing the intestinal commensal bacteria. 
 
Discussion & significance 
Intestinal microbiota is essential for maintenance of the intestinal epithelial barrier and 
development of the immune system. Paradoxically, GF mice are resistant to various types of 
carcinogenesis, indicating the tumor-promoting effects of intestinal microbiota. The findings 
of Iida et al., however, indicate that intestinal microbiota has crucial roles in inducing optimal 
responses to tumor therapy. CpG-ODN immunotherapy requires TNF production by myeloid 
cells primed with commensal bacteria, while platinum chemotherapy needs ROS generation 
by tumor-infiltrating inflammatory cells, which are stimulated with commensal bacteria. In 
the same issue of Science, Viaud et al. reported that cyclophosphamide translocates selected 
species of Gram-positive bacteria in intestinal microbiota into secondary lymphoid organs, 
where the bacteria stimulate memory Th1 and Th17 immune responses [11]. They further 
demonstrated that tumor-bearing GF or antibiotics-treated mice exhibited reduced responses 
to cyclophosphamide. Thus, intestinal microbiota can have great impacts on not only tumor 
immunotherapy but also various types of systemic chemotherapy. Moreover, cancer patients 
frequently receive wide-spectrum antibiotic treatment, which can potentially eradicate or 
disturb intestinal microbiota. Thus, the present observations may raise an alarm on the use of 
wide-spectrum antibiotics for cancer patients on chemotherapy and/or immunotherapy. 
 
Future Perspective 
The current paper by Iida et al. and the accompanying paper by Viaud et al. revealed the 
crucial involvement of intestinal commensal microbiota in the tumor response to some types 
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of chemotherapy. However, there remain several questions to be clarified. First, it is 
necessary to clarify whether intestinal microbiota have similar roles in tumor response to 
other types of chemotherapy than platinum agents and cyclophosphamide. Second, it is also 
required to elucidate how microbiota can induce a good response to chemotherapy at cellular 
and molecular levels. The most important question is whether intestinal microbiota as a 
whole or a specific species can confer the responsiveness to tumor therapy. If the latter is the 
case, it is mandatory to identify the responsible species. Despite the advent of next-generation 
sequencing technology, which has greatly expanded our knowledge on the composition of the 
intestinal microbiota, only a third of intestinal commensal bacteria can be cultured in vitro at 
present. Thus, the more detailed characterization of intestinal commensal bacteria at species 
levels will greatly advance our knowledge on the effects of intestinal microbiota on tumor 
therapy and will pave the way to improve the efficacy of chemotherapy and/or 
immunotherapy by modulating intestinal microbiota. 
 
Financial & competing interests disclosure  
There is no conflict of interests to disclose. 
 
Executive summary 
・Intestinal commensal microbiota is essential for many host physiological processes and 
contributes to promoting carcinogenesis. 
・The paper under evaluation revealed that intestinal microbiota is crucially involved in 
optimal tumor response to CpG-ODN immunotherapy and platinum chemotherapy. 
・The observations may raise the possibility that the modulation of intestinal microbiota can 
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